Talk:Viatris

This article is rated Stub-class on Wikipedia's content assessment scale. It is of interest to the following WikiProjects:

Companies Low‑importance This article is within the scope of WikiProject Companies, a collaborative effort to improve the coverage of companies on Wikipedia. If you would like to participate, please visit the project page, where you can join the discussion and see a list of open tasks.CompaniesWikipedia:WikiProject CompaniesTemplate:WikiProject Companiescompany articles Low This article has been rated as Low-importance on the project's importance scale. WikiProject Companies To-do: Here are some tasks awaiting attention: Article requests : Wikipedia:Requested articles/Business and economics/Companies Assess : Category:Unassessed company articles Copyedit : Category:Company articles needing attention Infobox : Category:Company articles needing infoboxes Maintain : Portal:Companies Stubs : Help expand stub articles located at Category:Company stubs Other : Tag company articles with the {{portal|Companies}} template Tag company talk pages with the {{WikiProject Companies}} project banner Answer requests for comments

The WP:COIRESPONSE . PittGuy123ABC (talk · contribs) has been paid by Viatris on their behalf.

This edit request by an editor with a conflict of interest has now been answered.

Hi. I work for Viatris, and I would like to request the following edit:

• Please add Viatris’ status as a NASDAQ Biotechnology Component^[1][2] to the "Traded as" section in the infobox.

Thank you for your help, PittGuy123ABC (talk) 18:39, 24 February 2022 (UTC)[reply]

Hi. I would like to add two more bullet points to this edit request.

• Since I posted the above edit request the company has had an important development in its history which should be added to the article. At the end of the History section, please add the following sentence: "In February 2022, Viatris announced an agreement where it will contribute to Biocon Biologics its biosimilars portfolio and related commercial and operational capabilities in exchange for up to $3.335 billion, including a stake of at least 12.9% in Biocon Biologics."^[3]
• Please add to the Infobox that Viatris is a component of the Russell1000.^[4][5]

Thanks. PittGuy123ABC (talk) 16:31, 9 March 2022 (UTC)[reply]

 Done - Suggested edits added - should be ok - Stay Safe and Healthy !! - Drbogdan (talk) 14:43, 24 March 2022 (UTC)[reply]

Hi Drbogdan. Thank you so much for your quick help with my edit request. Two small questions:

1. It seems that you mistakenly changed the company’s stock symbol to VTR which is the symbol for a similarly-named company. Could you please change this back to the correct symbol of VTRS?
2. Because I made this request in two stages, it seems that the first part of my request went unnoticed. To restate that request here, could you please add Viatris’ status as a NASDAQ Biotechnology Component^[6][7] to the "Traded as" section in the infobox?

Thanks again. PittGuy123ABC (talk) 15:59, 24 March 2022 (UTC)[reply]

 Done - @PittGuy123ABC: Thanks for your upd suggestions - should now be better - iac - Stay Safe and Healthy !! - Drbogdan (talk) 17:21, 24 March 2022 (UTC)[reply]

It looks like this request has been answered, so I am closing this as answered. Z1720 (talk) 01:24, 3 April 2022 (UTC)[reply]

This edit request by an editor with a conflict of interest has now been answered.

Hi Drbogdan. Thanks so much for implementing my previous edit request. I have one additional request as follows: Please add the following sentence to the end of the "Products" section. "Breyna (Budesonide and Formoterol Fumarate Dihydrate Inhalation Aerosol) received approval from the US FDA in March 2022 as the first generic version of Symbicort for the treatment of asthma and COPD.^[1][2] "

Thanks again. PittGuy123ABC (talk) 18:20, 28 March 2022 (UTC)[reply]

 Done - Stay Safe and Healthy !! - Drbogdan (talk) 19:09, 28 March 2022 (UTC)[reply]

Request has been answered, so I am closing this. Z1720 (talk) 01:25, 3 April 2022 (UTC)[reply]

This edit request by an editor with a conflict of interest has now been answered.

Hi. I saw that editor XyZAn recently added a sentence about Viatris's announcement of their agreement to acquire Oyster Point Pharma and Famy Life Sciences. I thank XyZAn for the addition, but I wonder if someone could slightly tweak the sentence to add information about the new division the company will create as a result of the planned acquisitions with a new, third-party source. The new sentence I propose is as follows:

In November 2022, Viatris announced agreements to acquire Oyster Point Pharma and Famy Life Sciences for a total of $700-$750 million in cash to create an ophthalmology division.^[1]

Also, since the acquisitions haven't yet been finalized, I think it would be most appropriate to remove the companies from the chart of Viatris's acquisitions until the deals are (hopefully) completed as planned in early 2023.

Thanks so much, PittGuy123ABC (talk) 16:33, 10 November 2022 (UTC)[reply]

 Done Ptrnext (talk) 22:26, 11 November 2022 (UTC)[reply]

Thanks so much Ptrnext for your quick response and edits. PittGuy123ABC (talk) 18:18, 23 November 2022 (UTC)[reply]

This edit request by an editor with a conflict of interest has now been answered.

Hi again. I would like to have some updates made to the page that reflect the finalization of recent deals, plus a few other edits so that the article is as current as possible.

• In the "History" section, add the following directly after the first sentence of the last paragraph, which ends with "including a stake of at least 12.9% in Biocon Biologics.":

The transaction was completed in November 2022.^[1]

• In the "History" section, add the following directly after the last sentence which begins "In November 2022,":

The acquisitions closed in January 2023.^[2][3]

• Please remove the (Acq pending) from Oyster Point Pharma and Famy Life Sciences on the "Viatris Acquisitions" chart, and replace with (Acq 2023) for both.
• In the Infobox, please add the parameter "Subsidiaries" and list "Oyster Point Pharma" and "Famy Life Sciences" as the subsidiaries.
• Finally, Please add the following sentence to the end of the History section:

In 2022, Viatris was recognized by Forbes as one of the world's best employers^[4] and by Newsweek as one of America's most responsible companies.^[5]

I am pinging Drbogdan who has helped here in the past. Thanks. PittGuy123ABC (talk) 18:18, 22 February 2023 (UTC)[reply]

 Done - @PittGuy123ABC: - newly installed edits seem ok - Stay Safe and Healthy !! - Drbogdan (talk) 19:40, 22 February 2023 (UTC)[reply]

Thanks so much for your help. You should stay safe and healthy, too. PittGuy123ABC (talk) 13:20, 23 February 2023 (UTC)[reply]

This edit request by an editor with a conflict of interest has now been answered.

Hello, I would like to update the page with information about the new CEO.

1. In the infobox, under Key people, please delete Michael Goettler and replace him with Scott A. Smith (CEO). Also delete Ian Read, as he is now retired as Director.
2. At the end of the History section, please add: On April 1, 2023, Scott A. Smith became Viatris' CEO, succeeding Michael Goettler. Smith previously served on the company's board since 2022. ^[1]

Once again pinging Drbogdan who has been so helpful with previous requests. Thank you. PittGuy123ABC (talk) 16:09, 3 April 2023 (UTC)[reply]

 Done @PittGuy123ABC: (and others) - Updated with edit suggestions - Should now be ok - Stay Safe and Healthy !!- Drbogdan (talk) 16:45, 3 April 2023 (UTC)[reply]

Drbogdan, thank you once again for your help in updating the page! PittGuy123ABC (talk) 17:50, 5 April 2023 (UTC)[reply]

This edit request by an editor with a conflict of interest has now been answered.

Hi. In order to keep the article up-to-date, please add the following sentences to the end of the History section but before the Predecessors sub-section:

In April 2023, Viatris was recognized by LinkedIn as one of the 25 best companies to work for in India,^[1] and one of the 25 best companies offering career development in Ireland.^[2]

In May 2023, USA Today included Viatris in its list of 400 US companies who have reduced their greenhouse gas emissions intensity from 2019 to 2021. ^[3]

In June 2023, Viatris was named to the Forbes Global 2000 list of the world's largest companies.^[4]

Pinging Drbogdan to help with this edit. Thanks so much, PittGuy123ABC (talk) 13:43, 21 June 2023 (UTC)[reply]

 Done - ok - added suggested text/refs to the main article - Stay Safe and Healthy !! - Drbogdan (talk) 14:36, 21 June 2023 (UTC)[reply]

Closing request per above. Z1720 (talk) 16:37, 22 June 2023 (UTC)[reply]

Thanks so much Drbogdan for your quick and helpful response. I took the liberty of closing the edit request. Wishing you good health and safety, too. PittGuy123ABC (talk) 14:37, 26 June 2023 (UTC)[reply]

This edit request by an editor with a conflict of interest has now been answered.

Hi. Can you kindly make the following changes to the History and Products sections, as follows:

• In the sixth paragraph in the History section that begins "In 2022, Viatris was recognized…" Please add the bolded words to update the sentence to the following:

In 2022 and 2023, Viatris was recognized by Forbes as one of the world's best employers. ^{[1] [2]} Also in 2022, Newsweek recognized Viatris as one of America's most responsible companies. ^[3]

• Please add the following update to the end of the History section:

In October 2023, Viatris reached agreements to divest from almost all of its OTC business, its women’s healthcare business, and its India-based active pharmaceutical ingredients business for a total of about $3.6 billion.^[4]

• Please replace the list of products in the "Products" section with the following list. The new list is in chronological order, adds newly available products, and removes products which Viatris no longer sells.

• Dolutegravir: In December 2020, received FDA approval to treat children with HIV/AIDS in low to middle income countries. The formulation is strawberry-flavored to make it easier to give to children and was made available at a 75% discount compared to previous treatments.^[5][6]
• Breyna (Budesonide and Formoterol Fumarate Dihydrate Inhalation Aerosol): In March 2022, received approval from the US FDA in March 2022 as the first generic version of Symbicort for the treatment of asthma and COPD.^[7][8]
• GA Depot (long-acting version of Glatiramer acetate): In August 2023, received New Drug Application acceptance from the US FDA as a once-monthly injection for the treatment of relapsing forms of multiple sclerosis.^[9][10]
• Abacavir/dolutegravir/lamivudine: In September 2023, received tentative US FDA approval for a New Drug Application through the President's Emergency Plan for AIDS Relief (PEPFAR) for the treatment of HIV-1 infection in pediatric patients.^[11][12]
• Ryzumvi(phentolamine ophthalmic solution 0.75%): In September 2023, received FDA approval for the treatment of mydriasis caused by adrenergic agonist or parasympatholytic agents or a combination of those drugs. It was previously known as Nyxol.^[13]

Thanks so much. Once again pinging Drbogdan who often steps up to help with editing this page. PittGuy123ABC (talk) 15:33, 1 February 2024 (UTC)[reply]

• I take a dim view of any and all "best company" rankings, but the Newsweek one is not acceptable because Newsweek
  is not considered a reliable source on English Wikipedia. (t · c) buidhe 16:09, 1 February 2024 (UTC)[reply
  ]

 Done Klbrain (talk) 00:08, 28 March 2024 (UTC)[reply]

Thank you Klbrain for your help with these changes. I appreciate your prompt response and implementation. Best regards. PittGuy123ABC (talk) 15:00, 28 March 2024 (UTC)[reply]